Creative Biolabs Launches Upgraded Lambda and M13 Phage Library Platforms to Accelerate Biotherapeutic Discovery

SHIRLEY, NY, April 30, 2026 /24-7PressRelease/ — As demand grows for faster gene discovery and more efficient biomolecule engineering, phage technologies have become indispensable tools across modern life sciences. Creative Biolabs’ newly upgraded lambda and M13 platforms offer complementary strengths that streamline the entire workflow—from genome‑scale exploration to high‑throughput functional screening.

High‑Fidelity Lambda Phage Genome Libraries
Lambda phage vectors remain a preferred system for constructing genomic libraries due to their ability to accommodate large DNA inserts of up to 25 kb while maintaining stable genomic representation. Creative Biolabs has modernized this classical platform with advanced technologies that significantly enhance library fidelity, coverage, and long‑term stability.

Key upgrades include:
• Acoustic DNA shearing for highly controlled and reproducible fragmentation
• Optimized size‑selection workflows ensuring ideal insert length distribution
• Ultra‑efficient in vitro packaging extracts, achieving titers exceeding 10⁹ pfu/µg DNA
• Bias‑minimized protocols tailored for complex or non‑model organisms

These innovations enable researchers to capture rare genomic elements and construct libraries with exceptional complexity. The platform supports applications such as whole‑genome mapping, metagenomics, gene discovery, and functional screening.

M13 Phage Display Libraries: Driving High‑Performance Biotherapeutic Discovery
Creative Biolabs’ upgraded M13 phage display platform supports the construction of ultra‑diverse libraries—often reaching 10¹⁰ to 10¹¹ unique variants—ideal for identifying high‑affinity antibodies, peptides, and other ligands.

Platform highlights include:
• Multiple display formats, including pIII monovalent and pVIII multivalent configurations
• Trimer Codon Technology to eliminate stop codons and ensure uniform amino acid distribution
• High‑efficiency electroporation for maximal library diversity
• NGS‑based validation to confirm diversity, integrity, and functional quality

These capabilities make the platform a powerful engine for antibody discovery, epitope mapping, protein engineering, and diagnostic development.

“Phage‑based technologies continue to shape the future of biotechnology,” said a spokesperson for Creative Biolabs. “Our upgraded lambda and M13 platforms reflect our commitment to delivering advanced, customizable, and reliable solutions that help researchers achieve meaningful scientific breakthroughs.”

Frequently Asked Questions
Q1: Can I display large proteins on M13 phage?
A: Yes. While pIII is generally better for large proteins, we have successfully displayed proteins up to 50-60 kDa. However, larger inserts may affect phage assembly or infectivity.

Q2: Can you construct libraries from non-model organisms?
A: Yes. We have extensive experience working with plant genomes, marine microbes, and diverse animal species. Our custom protocols are designed to handle challenges such as high GC content and repetitive sequences commonly found in non‑model organisms.

To discuss your research needs, please visit https://www.creative-biolabs.com/.

About Creative Biolabs
Creative Biolabs is a global provider of phage display technologies, antibody engineering services, and custom biotechnology solutions. With more than 20 years of experience, the company supports academic, pharmaceutical, and industrial partners in advancing innovation across genomics, immunology, and therapeutic development.

—
For the original version of this press release, please visit 24-7PressRelease.com here